- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 5/08 - Tripeptides
Patent holdings for IPC class C07K 5/08
Total number of patents in this class: 670
10-year publication summary
|
40
|
53
|
49
|
50
|
40
|
37
|
33
|
20
|
26
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Purdue Research Foundation | 3869 |
28 |
| Bristol-myers Squibb Company | 4797 |
15 |
| ISP Investments Inc. | 447 |
15 |
| Ajinomoto Co., Inc. | 2278 |
9 |
| Hoffmann-La Roche Inc. | 3722 |
8 |
| The Regents of the University of California | 20594 |
8 |
| Onyx Therapeutics, Inc. | 67 |
8 |
| Genentech, Inc. | 4090 |
7 |
| Regeneron Pharmaceuticals, Inc. | 4638 |
7 |
| DSM IP Assets B.V. | 5430 |
6 |
| Novozymes A/S | 3354 |
6 |
| Merck Sharp & Dohme LLC | 3736 |
6 |
| Boehringer Ingelheim International GmbH | 4494 |
5 |
| Agency for Science, Technology and Research | 3699 |
5 |
| InterMune, Inc. | 48 |
5 |
| Rhythm Pharmaceuticals, Inc. | 93 |
5 |
| Supadelixir Inc. | 24 |
5 |
| California Institute of Technology | 4021 |
4 |
| University of Florida Research Foundation, Inc. | 4156 |
4 |
| Enanta Pharmaceuticals, Inc. | 433 |
4 |
| Other owners | 510 |